美国人体微生物组市场，按产品（益生菌、益生元、诊断测试、药物、补充剂、粪便微生物群移植等）、应用（治疗和诊断）、疾病（传染病、皮肤病、自身免疫性疾病、代谢紊乱、胃肠道疾病、癌症、精神障碍、艰难梭菌感染、原发性高氧脲溶液相等）、技术（基因组学、蛋白质组学和代谢组学）、类型（小分子和生物制剂）、最终用户（医院药房、零售药房、网上药房、大卖场/超市、诊所等）、分销商（直接招标和零售销售）行业趋势和预测到 2029 年。
美国市场分析与洞察
微生物群是指与人类相关的微生物分类群，微生物组是指“这些微生物及其基因的目录”。所有微生物群的集合，存在于人体组织和生物体液上或体内，以及它们所处的相应解剖部位，包括皮肤、乳腺、精液、子宫、卵泡、肺、唾液、口腔黏膜、结膜、胆道等。人类微生物群由每个人身上携带的 10-100 万亿个共生微生物细胞组成，主要是肠道中的细菌。人类微生物组由这些细胞携带的基因组成。
美国人类微生物组市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场以 23.9% 的复合年增长率增长，预计到 2029 年将达到 15.2806 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为2019-2014） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按产品（益生菌、益生元、诊断测试、药物、补充剂、粪便微生物群移植等）、应用（治疗和诊断）、疾病（传染病、皮肤病、自身免疫性疾病、代谢紊乱、胃肠道疾病、癌症、精神障碍、艰难梭菌感染、原发性高氧脲原体等）、技术（基因组学、蛋白质组学和代谢组学）、类型（小分子和生物制剂）、最终用户（医院药房、零售药房、网上药房、大卖场/超市、诊所等）、分销商（直接招标和零售销售） |
|
覆盖国家 |
我们 |
|
涵盖的市场参与者 |
在市场上开展业务的主要公司包括 4D pharma plc、Evelo Biosciences, Inc.、Viome Life Sciences, Inc.、Finch Therapeutics Group, Inc.、OptiBiotix HEALTH PLC、BiomX、Sun Genomics、Metabiomics、Osel Inc、Ferring BV、Merck KGaA、Assembly Biosciences, Inc.、Synthetic Biologics, Inc.、FlightPath Biosciences, Inc.、Vedanta Biosciences, Inc. 和 Second Genome 等 |
市场定义
微生物组是人体内和体表所有微生物（细菌、真菌、原生动物和病毒）的遗传物质。一个人的微生物组中所有微生物的基因数量是人类基因组中基因数量的 200 倍。微生物组分析最广泛使用的鉴定方法是 16s rRNA 测序。对这些微生物群的鉴定和了解已导致这些微生物通过益生菌、益生元和其他相关药物等各种产品应用于改善人类健康。
美国人类微生物组市场动态
驱动程序
-
生活方式和慢性病患病率上升
由于全球慢性病发病率上升，对有效治疗产品的需求在未来几年内将会增加。因此，发病率上升预计将成为市场增长的推动力。
-
宏基因组学和下一代测序技术不断进步
宏基因组学是通过功能基因筛选从特定环境中获取微生物，研究其多样性、遗传关系、功能活性以及与环境的关系等的新方法，而测序技术则是从散弹枪测序、高通量测序、二代测序、三代测序发展而来，用于诊断或治疗疾病，二代测序和三代测序显示出快速检测微生物的优势。
此外，技术进步的提高、公共和私人组织为传播意识而采取的举措不断增多以及政府资金的增加都是推动市场增长的因素。
因此，测序技术的进步将推动市场的发展。
机会
-
医疗支出增加
与人体微生物组相关的产品（如益生菌、益生元、药物和补充剂）价格昂贵。普通的低收入和中等收入家庭无法充分治疗肠道相关疾病。政府正致力于增加医疗支出，以获得可用的治疗方法和新产品。
此外，主要参与者的战略举措和医疗保健支出的增长将为 2022-2029 年预测期内的市场提供结构完整性和未来机会。
限制/挑战
- 缺乏熟练的专业人员
然而，缺乏技术专业知识和证明菌群失调与疾病之间因果关系的障碍将阻碍人类微生物组市场的增长速度。此外，在上述预测期内，具体识别的困难和严格的规章制度将进一步挑战市场。
COVID-19 对美国人体微生物组市场的影响
COVID-19 对市场产生了负面影响。疫情期间的封锁和隔离使疾病管理和服药依从性变得复杂。无法获得医疗机构的常规治疗和药物管理将进一步影响市场。社会隔离会增加压力、绝望和社会支持，所有这些都可能导致疫情期间服药依从性的降低。
近期发展
- 2020 年 3 月，Optibiotix Health PLC 对 ProBiotix Health 的 LPLDL 人体干预研究进行了研究，结果显示其在降低胆固醇方面取得了令人鼓舞的成果
美国人类微生物组市场范围
美国人体微生物组市场细分为产品、应用、技术、类型、疾病、最终用户和分销商。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
产品
- 益生菌
- 益生元
- 诊断测试
- 药物
- 补充剂
- 粪便微生物群移植
- 其他的
根据产品，市场分为益生菌、益生元、诊断测试、药物、补充剂、粪便微生物群移植和其他。
应用
- 治疗
- 诊断
根据应用，市场分为治疗和诊断。
疾病
- 传染病
- 皮肤病
- 自身免疫性疾病
- 代谢紊乱
- 胃肠道疾病
- 癌症
- 精神障碍
- 艰难梭菌感染
- 初级高氧脲溶液阶段
- 其他的
根据疾病，市场细分为传染病、皮肤病、自身免疫性疾病、代谢紊乱、胃肠道疾病、癌症、精神疾病、艰难梭菌感染、原发性高氧尿素溶解期和其他。
技术
- 基因组学
- 蛋白质组学
- 代谢组学
根据技术，市场分为基因组学、蛋白质组学和代谢组学。
类型
- 小分子
- 生物
根据类型，市场分为小分子和生物制剂。
最终用户
- 医院药房
- 零售药店
- 网上药店
- 大卖场/超市
- 诊所
- 其他的
根据最终用户，市场细分为医院药房、零售药房、网上药房、大卖场/超市、诊所和其他
分销商
-
直接招标
-
零售销售
根据分销商，市场分为直接招标和零售。
美国人类微生物组市场区域分析/见解
对美国人类微生物组市场进行了分析，并按上述产品、应用、疾病、技术、类型、最终用户和分销商提供了市场规模洞察和趋势。
美国人类微生物组市场报告涵盖的国家是美国
由于美国医疗保健支出不断增加，美国人体微生物组市场占据主导地位
报告的国家部分还提供了影响单个市场因素和市场法规变化，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和人类微生物组市场份额分析
美国人体微生物组市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
在美国市场运营的一些主要参与者包括 4D pharma plc、Evelo Biosciences, Inc.、Viome Life Sciences, Inc.、Finch Therapeutics Group, Inc.、OptiBiotix HEALTH PLC、BiomX、Sun Genomics、Metabiomics、Osel Inc.、Ferring BV、Merck KGaA、Assembly Biosciences, Inc.、Synthetic Biologics, Inc.、FlightPath Biosciences, Inc.、Vedanta Biosciences, Inc. 和 Second Genome 等。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、美国与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.S. HUMAN MICROBIOME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 GLOBAL HUMAN MICROBIOME MARKET ANALYSIS
4.4 GUT MICROBIOME AND DIAGNOSTIC
5 EPIDEMIOLOGY
5.1 EPIDEMIOLOGY CANCER
5.2 EPIDEMIOLOGY DERMATOLOGICAL DISORDERS
5.3 EPIDEMIOLOGY GASTRIC DISORDERS
5.4 EPIDEMIOLOGY IMMUNE DISORDERS
5.5 EPIDEMIOLOGY METABOLIC DISORDERS
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
7 INDUSTRY INSIGHT
7.1 PATENT ANALYSIS
7.2 PATENT FLOW DIAGRAM
8 REGULATORY FRAMEWORKS
8.1 UNITED STATES
8.2 EUROPE
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING PREVALENCE OF LIFESTYLE AND CHRONIC DISEASES
9.1.2 HUMAN MICROBIOME THERAPEUTIC DEVELOPMENT FOR DISEASE TREATMENT
9.1.3 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING
9.2 RESTRAINTS
9.2.1 BARRIERS PROVING THE CAUSAL LINK BETWEEN DYSBIOSIS AND DISEASES
9.2.2 LACK OF TECHNOLOGY EXPERTISE
9.3 OPPORTUNITIES
9.3.1 RISE IN HEALTHCARE EXPENDITURE
9.3.2 INCREASING RESEARCH AND DEVELOPMENT
9.4 CHALLENGE
9.4.1 RISK ASSOCIATED WITH HUMAN MICROBIOME PRODUCTS
10 U.S. HUMAN MICROBIOME MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 PROBIOTICS
10.2.1 BRANDED
10.2.1.1 OPTIPAC-PREBIOTICS FIBRE
10.2.1.2 ENZYMEDICA-PREBIOTICS DRINK MIX
10.2.1.3 SWEETBIOTIX
10.2.1.4 OTHERS
10.2.2 GENERICS
10.3 PREBIOTICS
10.3.1 BRANDED
10.3.1.1 BIOM PROBIOTIC
10.3.1.2 BIOM D FEND
10.3.1.3 FLORE GUT MICROBIOME TEST
10.3.1.4 REVITIFY
10.3.1.5 SYMBIOTIC YOGURT
10.3.1.6 SYMBIOTIC
10.3.1.7 LPLDL
10.3.1.8 LPGOS
10.3.1.9 OTHERS
10.3.2 GENERICS
10.4 SUPPLEMENTS
10.4.1 CHOLBIOME
10.4.2 LPGOS
10.4.3 WELL BIOME
10.4.4 FLORE BOOM
10.4.5 FLORE DEFENCE
10.4.6 FLORE BALANCE
10.4.7 BIOM
10.4.8 REVITIFY
10.4.9 FLORE
10.4.10 BIOM D FEND
10.4.11 SLIM BIOME
10.4.12 OTHERS
10.5 DIAGNOSTICS TESTS
10.5.1 FLORE GUT MICROBIOME TEST
10.5.2 FLORE 360
10.5.3 BIOME MICROBIOME TEST
10.5.4 SUPER GUT MICROBIOME HEALTH TEST
10.5.5 HEALTH INTELLIGENCE TEST
10.5.6 GUT INTELLIGENCE TEST
10.5.7 X MARKER
10.5.8 ATLAS MICROBIOME TEST
10.5.9 1TEST 1
10.5.10 LIFE KIT
10.5.11 FOR A
10.5.12 OTHERS
10.6 DRUGS
10.6.1 OXABACT
10.6.2 SINTAX
10.6.3 SYNBIOTIC YOGURT
10.6.4 SYNBIOTIC 7
10.6.5 MICRORX
10.6.6 SLIM BIOME
10.6.7 SLIM BIOME MEDICAL
10.6.8 LPLDL
10.6.9 CHOLBIOME
10.6.10 OTHERS
10.7 FECAL MICROBIOTA TRANSPLANT
10.8 OTHERS
11 U.S. HUMAN MICROBIOME MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 THERAPEUTIC
11.2.1 SINGLE STRAIN OR MULTI-STRAIN CONSORTIA
11.2.2 LIQUID OR DRIED BULK DRUG SUBSTANCE
11.2.3 SOLID ORAL DOSE
11.2.4 OTHERS
11.3 DIAGNOSTIC
11.3.1 IRRITABLE BOWEL SYNDROME
11.3.2 LEAKY GUT SYNDROME
11.3.3 DIABETES
11.3.4 BACTERIAL VAGINOSIS
11.3.5 GINGITIVIS
11.3.6 TRICHOMONIASIS
11.3.7 VAGINAL CANDIDIASIS
12 U.S. HUMAN MICROBIOME MARKET, BY DISEASE
12.1 OVERVIEW
12.2 INFECTIOUS DISEASE
12.2.1 HELICOBACTER PYLORI
12.2.2 C. DIFFICILE INFECTIONS
12.2.3 BACTERIAL VAGINOSIS
12.2.4 OTHERS
12.3 GASTROINTESTINAL DISORDERS
12.4 C. DIFFICILE INFECTION
12.5 METABOLIC DISORDER
12.5.1 DIABETES
12.5.2 OBESITY
12.5.3 ENDOCRINE
12.5.4 NON ALCOHOLIC LIVER DISEASE
12.6 AUTOIMMUNE DISORDER
12.7 CANCER
12.8 MENTAL DISORDER
12.9 DERMATOLOGICAL DISORDERS
12.9.1 ATOPIC DERMATITIS
12.9.2 ROSACEA
12.9.3 ACNE
12.9.4 OTHERS
12.1 PRIMARY HYPEROXYUREASOLUTION-PHASE
12.11 OTHERS
13 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 GENOMICS
13.2.1 SEQUENCING
13.2.1.1 16S RRNA SEQUENCING METHOD
13.2.1.2 SHOTGUN METAGENOMICS SEQUENCING
13.2.1.3 WHOLE GENOME SEQUENCING
13.2.1.4 OTHER
13.2.2 POLYMERASE CHAIN REACTION
13.2.3 OTHER GENOMIC TECHNIQUES
13.2.4 ORGAN TRANSPLANTATION
13.2.5 OTHER CLINICAL APPLICATION
13.3 PROTEOMICS
13.3.1 EXPRESSION PROTEOMICS
13.3.2 FUNCTIONAL PROTEOMICS
13.3.3 STRUCTURAL PROTEOMICS
13.4 METABOLIMICS
13.4.1 TARGETED ANALYSIS
13.4.2 METABOLITE PROFILING
13.4.3 METABOLIC FINGERPRINTING
14 U.S. HUMAN MICROBIOME MARKET, BY TYPE
14.1 OVERVIEW
14.2 SMALL MOLECULE
14.3 BIOLOGIC
15 U.S. HUMAN MICROBIOME MARKET, BY END USER
15.1 OVERVIEW
15.2 ONLINE PHARMACIES
15.3 HYPERMARKET & SUPERMARKET
15.4 RETAIL PHARMACIES
15.5 HOSPITAL PHARMACIES
15.6 CLINICS
15.7 OTHERS
16 U.S. HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL SALES
16.3 DIRECT TENDERS
17 U.S. HUMAN MICROBIOME MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: U.S.
18 COMPANY PROFILE
18.1 OPTIBIOTIX HEALTH PLC
18.1.1 COMPANY SNAPSHOT
18.1.2 PRODUCT PORTFOLIO
18.1.3 RECENT DEVELOPMENT
18.2 MERCK KGAA
18.2.1 COMPANY SNAPSHOT
18.2.2 PRODUCT PORTFOLIO
18.2.3 RECENT DEVELOPMENTS
18.3 FINCH THERAPEUTICS GROUP, INC
18.3.1 COMPANY SNAPSHOT
18.3.2 PIPELINE PRODUCT PORTFOLIO
18.3.3 RECENT DEVELOPMENT
18.4 FERRING B.V.
18.4.1 COMPANY SNAPSHOT
18.4.2 PIPELINE PRODUCT PORTFOLIO
18.4.3 RECENT DEVELOPMENTS
18.5 ATLAS BIOMED GROUP LIMITED
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 ENTEROME
18.6.1 COMPANY SNAPSHOT
18.6.2 PIPELINE PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 ASSEMBLY BIOSCIENCES, INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 PIPELINE PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 BIOMX
18.8.1 COMPANY SNAPSHOT
18.8.2 PIPELINE PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 EMBION TECHNOLOGIES S.A.
18.9.1 COMPANY SNAPSHOT
18.9.2 PIPELINE PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.1 EVELO BIOSCIENCES, INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PIPELINE PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 FLIGHTPATH BIOSCIENCES, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PIPELINE PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 GNUBIOTICS SCIENCES
18.12.1 COMPANY SNAPSHOT
18.12.2 PIPELINE PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 IMMURON
18.13.1 COMPANY SNAPSHOT
18.13.2 PIPELINE PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.14 LUXIA SCIENTIFIC
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 METABIOMICS
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 OSEL INC
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 OXTHERA.
18.17.1 COMPANY SNAPSHOT
18.17.2 PIPELINE PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.18 SECOND GENOME
18.18.1 COMPANY SNAPSHOT
18.18.2 PIPELINE PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SERES THERAPEUTICS
18.19.1 COMPANY SNAPSHOT
18.19.2 PIPELINE PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENTS
18.2 SUN GENOMICS
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
18.21 SYNTHETIC BIOLOGICS, INC..
18.21.1 COMPANY SNAPSHOT
18.21.2 PIPELINE PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 SYNLOGIC
18.22.1 COMPANY SNAPSHOT
18.22.2 PIPELINE PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENTS
18.23 VEDANTA BIOSCIENCES, INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PIPELINE PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENTS
18.24 VIOME LIFESCIENCES, US
18.24.1 COMPANY SNAPSHOT
18.24.2 PRODUCT PORTFOLIO
18.24.3 RECENT DEVELOPMENT
18.25 YSOPIA BIOSCIENCE
18.25.1 COMPANY SNAPSHOT
18.25.2 PIPELINE PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENT
18.26 4D PHARMA PLC
18.26.1 COMPANY SNAPSHOT
18.26.2 PRODUCT PORTFOLIO
18.26.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 PATENT ANALYSIS
TABLE 2 U.S. HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 U.S. PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 4 U.S. BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 U.S. PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 6 U.S. BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 U.S. SUPPLEMENTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 8 U.S. DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 U.S. DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 10 U.S. HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 U.S. THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 U.S. DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 U.S. HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 14 U.S. INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 15 U.S. METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 16 U.S. DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 17 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 18 U.S. GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 19 U.S. SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 20 U.S. PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 21 U.S. METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 22 U.S. HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 U.S. HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 U.S. HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 U.S. HUMAN MICROBIOME MARKET: SEGMENTATION
FIGURE 2 U.S. HUMAN MICROBIOME MARKET: DATA TRIANGULATION
FIGURE 3 U.S. HUMAN MICROBIOME MARKET: DROC ANALYSIS
FIGURE 4 U.S. HUMAN MICROBIOME MARKET: U.S. VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. HUMAN MICROBIOME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. HUMAN MICROBIOME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. HUMAN MICROBIOME MARKET: DBMR MARKET POSITION GRID
FIGURE 8 U.S. HUMAN MICROBIOME MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 U.S. HUMAN MICROBIOME MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. HUMAN MICROBIOME MARKET: SEGMENTATION
FIGURE 11 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING ARE EXPECTED TO DRIVE THE U.S. HUMAN MICROBIOME MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 PROBIOTICS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. HUMAN MICROBIOME MARKET IN 2022 & 2029
FIGURE 13 PATENT FLOW DIAGRAM FOR DRUGS IN THE U.S.
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.S. HUMAN MICROBIOME MARKET
FIGURE 15 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, 2021
FIGURE 16 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, 2022-2029 (USD MILLION)
FIGURE 17 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 18 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, 2021
FIGURE 20 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 21 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 22 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, 2021
FIGURE 24 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, 2022-2029 (USD MILLION)
FIGURE 25 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, CAGR (2022-2029)
FIGURE 26 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 27 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, 2021
FIGURE 28 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 29 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 30 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 U.S. HUMAN MICROBIOME MARKET: BY TYPE, 2021
FIGURE 32 U.S. HUMAN MICROBIOME MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 33 U.S. HUMAN MICROBIOME MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 34 U.S. HUMAN MICROBIOME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 35 U.S. HUMAN MICROBIOME MARKET: BY END USER, 2021
FIGURE 36 U.S. HUMAN MICROBIOME MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 37 U.S. HUMAN MICROBIOME MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 U.S. HUMAN MICROBIOME MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 41 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 U.S. HUMAN MICROBIOME MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
